Home » Stocks » QGEN

Qiagen N.V. (QGEN)

Stock Price: $46.89 USD -0.75 (-1.57%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Pre-market: $45.86 -1.03 (-2.20%) May 11, 8:06 AM
Market Cap 10.78B
Revenue (ttm) 2.07B
Net Income (ttm) 448.58M
Shares Out 228.41M
EPS (ttm) 1.92
PE Ratio 24.46
Forward PE 19.34
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $46.89
Previous Close $47.64
Change ($) -0.75
Change (%) -1.57%
Day's Open 47.83
Day's Range 46.80 - 47.79
Day's Volume 415,941
52-Week Range 41.98 - 59.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.

6 days ago - Zacks Investment Research

Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million. Adjusted EPS $0....

1 week ago - Benzinga

Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

U.S.-German genetic testing specialist Qiagen reported slightly better-than-expected quarterly earnings on Monday as sales growth for non-coronavirus products added to high demand for its COVID-19 testi...

1 week ago - Reuters

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN exceeds outlook in first quarter 2021 results, reaffirms sales growth and profitability outlook for full-year 2021

1 week ago - Business Wire

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces EZ2 Connect instrument line for automated sample processing in research, forensics and diagnostics

1 week ago - Business Wire

HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN with DiaSorin, announce the launch of LIAISON® LymeDetect® Assay based on QuantiFERON technology for early diagnosis of Lyme Borreliosis

2 weeks ago - Business Wire

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN launches artus Prep&Amp as CE-marked SARS-CoV-2 test offering up to threefold increase in daily lab testing capacity

2 weeks ago - Business Wire

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report First Quarter 2021 Results

3 weeks ago - Business Wire

Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.

3 weeks ago - Zacks Investment Research

QGEN vs. TECH: Which Stock Is the Better Value Option?

Other stocks mentioned: TECH
1 month ago - Zacks Investment Research

Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.

Other stocks mentioned: HOLX, OMI
1 month ago - Zacks Investment Research

QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.

1 month ago - Zacks Investment Research

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN adds to COVID-19 portfolio with new ultra-fast sequencing solution for high-throughput genomic surveillance

1 month ago - Business Wire

QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.

1 month ago - Zacks Investment Research

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN receives FDA Emergency Use Authorization for NeuMoDx multiplex test expanding COVID-19 portfolio

1 month ago - Business Wire

QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.

2 months ago - Zacks Investment Research

QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.

2 months ago - Zacks Investment Research

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces 20-F annual report filing for 2020 results

2 months ago - Business Wire

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN launches QIAsphere cloud-based connectivity solution to enhance QIAstat-Dx capabilities in digital diagnostics

2 months ago - Business Wire

QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.

2 months ago - Zacks Investment Research

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs

2 months ago - Business Wire

Qiagen NV (NYSE: QGEN) and Inovio Pharmaceuticals Inc (NASDAQ: INO) expanded their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products usin...

Other stocks mentioned: INO
2 months ago - Benzinga

PLYMOUTH MEETING, Pa. & GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's...

2 months ago - Business Wire

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN expands Supervisory Board with appointment of a new member

2 months ago - Business Wire

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

3 months ago - Zacks Investment Research

Qiagen (QGEN) delivered earnings and revenue surprises of 3.03% and 3.51%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Qiagen (NYSE:QGEN) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 41.67% year over year to $0.68, which beat the est...

3 months ago - Benzinga

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN beats outlook for fourth quarter and full-year 2020, reaffirms expectations for further growth in 2021

3 months ago - Business Wire

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN adds dPCR platform QIAcuity to growing portfolio of COVID-19 testing solutions for wastewater and mutation testing

3 months ago - Business Wire

QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.

3 months ago - Zacks Investment Research

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report Fourth Quarter and Full-Year 2020 Results

3 months ago - Business Wire

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN plans to resubmit EUA submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the first quarter of 2021

3 months ago - Business Wire

GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN confirms effectiveness of its SARS-CoV-2 PCR tests in the face of mutations of the coronavirus

3 months ago - Business Wire

The resurgence in coronavirus infections is drawing attention back to the diagnostic testing space.

Other stocks mentioned: ABT, BDX, DGX, HOLX, LH, QDEL
3 months ago - Zacks Investment Research

VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces appointment of new Supervisory Board member

4 months ago - Business Wire

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

4 months ago - Zacks Investment Research

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN underlines and innovates its commitment to sustainability with a EUR 400mn sustainability-linked credit facility

4 months ago - Business Wire

VENLO, The Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces the successful pricing of the following series of transac...

4 months ago - Business Wire

QIAGEN's (QGEN) latest RUO solution is expected to provide better insights into the course of the COVID-19 infection and aid in vaccine development and deployment.

5 months ago - Zacks Investment Research

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN increases outlook for 2020 and 2021

5 months ago - Business Wire

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN to launch QuantiFERON SARS-CoV-2 for research into causes, spread and control of COVID-19 through T-cell response

5 months ago - Business Wire

Much healthcare investment attention is dominated by COVID-19, but other needs persist, including diagnostics provision and research. One investor asks about QIAGEN's current prospects and competitors. ...

5 months ago - Seeking Alpha

Is QIAGEN (QGEN) a great pick from the value investor's perspective right now? Read on to know more.

5 months ago - Zacks Investment Research

Qiagen has been a beneficiary of COVID related tailwinds particularly as related to COVID testing, which has driven strong revenue growth and profitability. Several new products set to come to market in...

5 months ago - Seeking Alpha

QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.

Other stocks mentioned: BNTX
5 months ago - Zacks Investment Research

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN--QIAGEN collaborates with BioNTech on companion diagnostics development for HPV-associated squamous cell carcinoma of the head and neck

5 months ago - Business Wire

Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.

5 months ago - Zacks Investment Research

QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.

5 months ago - Zacks Investment Research

About QGEN

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sa... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 28, 1996
CEO
Thierry Bernard
Employees
5,750
Stock Exchange
NYSE
Ticker Symbol
QGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for Qiagen stock is "Buy." The 12-month stock price forecast is 58.87, which is an increase of 25.55% from the latest price.

Price Target
$58.87
(25.55% upside)
Analyst Consensus: Buy